We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Esperion's Combo Cholesterol Candidate Enters Phase III
Read MoreHide Full Article
Esperion Therapeutics, Inc. (ESPR - Free Report) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Merck & Co., Inc.’s (MRK - Free Report) Zetia (ezetimibe) (10 mg) for an LDL-C or “bad cholesterol” lowering indication.
Esperion is evaluating bempedoic acid as monotherapy in an ongoing phase III study for an LDL-C lowering indication. The bridging study, on initiation, will be conducted alongside the ongoing study and will support approval of once-daily, oral combination pill.
Esperion’s year-to-date share price movement shows that the company has significantly outperformed the Zacks classified Medical - Drugs industry. Specifically, the stock surged 249.3% during this period, while the industry increased 10.1%.
The bridging study will evaluate the combination pill in patients with hypercholesterolemia and with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), including high cardiovascular risk primary prevention patients. The primary endpoint of the study was to evaluate the efficacy and safety of the oral administration of the combination therapy in adequately controlling the LDL-C.
Esperion expects to finalize the phase III protocol and initiate the study in the fourth quarter of 2017 with top-line data anticipated by the end of 2018. A previously completed phase II study evaluating the combination therapy demonstrated a 48% reduction of LDL-C.
The company also plans to file for regulatory approvals in the U.S. and EU for both the monotherapy and combination pill by the first half of 2019.
The two therapies strengthen Esperion’s portfolio with two separate, convenient and cost-effective non-statin therapies, which can be administered orally for controlling LDL-C. Moreover, the combination pill has potential to address far more patients than bempedoic acid alone.
Per the press release, approximately 150 million people have elevated LDL-C in the U.S. and Europe. Of these, an estimated 40 million patients in the U.S. are using statins, which is intolerable in 5% to 20% of this population. The successful completion of the studies will be a positive for the company as it will bring the therapies closer to approval.
Regeneron’s earnings estimates moved up from $10.17 to $10.52 for 2017 and from $10.90 to $12.10 for 2018, over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters, with an average beat of 0.45%. Its share price is up 36.8% so far this year.
Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company came up with positive earnings surprises each of the last four quarters, with an average beat of 55.83%. Its shares are up 61.4% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Esperion's Combo Cholesterol Candidate Enters Phase III
Esperion Therapeutics, Inc. (ESPR - Free Report) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Merck & Co., Inc.’s (MRK - Free Report) Zetia (ezetimibe) (10 mg) for an LDL-C or “bad cholesterol” lowering indication.
Esperion is evaluating bempedoic acid as monotherapy in an ongoing phase III study for an LDL-C lowering indication. The bridging study, on initiation, will be conducted alongside the ongoing study and will support approval of once-daily, oral combination pill.
Esperion’s year-to-date share price movement shows that the company has significantly outperformed the Zacks classified Medical - Drugs industry. Specifically, the stock surged 249.3% during this period, while the industry increased 10.1%.
The bridging study will evaluate the combination pill in patients with hypercholesterolemia and with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), including high cardiovascular risk primary prevention patients. The primary endpoint of the study was to evaluate the efficacy and safety of the oral administration of the combination therapy in adequately controlling the LDL-C.
Esperion expects to finalize the phase III protocol and initiate the study in the fourth quarter of 2017 with top-line data anticipated by the end of 2018. A previously completed phase II study evaluating the combination therapy demonstrated a 48% reduction of LDL-C.
The company also plans to file for regulatory approvals in the U.S. and EU for both the monotherapy and combination pill by the first half of 2019.
The two therapies strengthen Esperion’s portfolio with two separate, convenient and cost-effective non-statin therapies, which can be administered orally for controlling LDL-C. Moreover, the combination pill has potential to address far more patients than bempedoic acid alone.
Per the press release, approximately 150 million people have elevated LDL-C in the U.S. and Europe. Of these, an estimated 40 million patients in the U.S. are using statins, which is intolerable in 5% to 20% of this population. The successful completion of the studies will be a positive for the company as it will bring the therapies closer to approval.
Esperion Therapeutics, Inc. Price and Consensus
Esperion Therapeutics, Inc. Price and Consensus | Esperion Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the healthcare sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Enzo Biochem, Inc. (ENZ - Free Report) . Regeneron sports a Zacks Rank #1 (Strong Buy) while Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings estimates moved up from $10.17 to $10.52 for 2017 and from $10.90 to $12.10 for 2018, over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters, with an average beat of 0.45%. Its share price is up 36.8% so far this year.
Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company came up with positive earnings surprises each of the last four quarters, with an average beat of 55.83%. Its shares are up 61.4% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>